Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 10/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708344 | 0.81 | NAAA (0.49) | NAAAPIK3CDFAAHRIPK1 | |
| SCHEMBL16815045 | 0.80 | NAAA (0.41) | NAAAPIK3CDFAAH | |
| SCHEMBL1027659 | 0.76 | — | — | |
| SCHEMBL7569177 | 0.75 | NAAA (0.48) | NAAAFAAH | |
| SCHEMBL16129066 | 0.75 | NAAA (0.54) | NAAAPIK3CDFAAH | |
| SCHEMBL1563999 | 0.75 | USP2 (0.49) | NAAAPIK3CD | |
| SCHEMBL1455883 | 0.73 | — | — | |
| SCHEMBL3145817 | 0.71 | — | — | |
| SCHEMBL18832718 | 0.71 | — | — | |
| SCHEMBL11254970 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-5972237-A | USED AS COLD BLEACH ACTIVATORS OR OPTICAL BRIGHTENERS IN DETERGENTS, CLEANERS AND BLEACHES AND IN DISINFECTANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-26 | — | — | US | disclosed |
| EP-0826025-A1 | USE OF HETEROCYCLIC COMPOUNDS AS ACTIVATORS FOR INORGANIC PEROXY COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036686-A1 | USE OF HETEROCYCLIC COMPOUNDS AS ACTIVATORS FOR INORGANIC PEROXY COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | NAAA 3181/4885PIK3CD 4518/4885FAAH 3152/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | NAAA 3181/4885PIK3CD 4518/4885FAAH 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.